U.S., Sept. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07196111) titled 'BAFFR CAR-T Treatment for Relapsed/Refractory B-cell Tumors' on Sept. 19.
Brief Summary: This study is a single-arm, multicenter clinical trial of dose escalation and dose expansion.
Study Start Date: Oct. 10
Study Type: INTERVENTIONAL
Condition:
B Acute Lymphoblastic Leukemia/Lymphoma
Intervention:
BIOLOGICAL: BAFFR CAR-T
A single infusion of BAFFR CAR-T Injection administered intravenously.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Guangzhou Bio-gene Technology Co., Ltd
Disclaimer: Curated by HT Syndication....